Log in

NASDAQ:BIOS - BioScrip Stock Price, Forecast & News

$4.20
+0.10 (+2.44 %)
(As of 01/21/2020 03:11 AM ET)
Today's Range
$4.04
Now: $4.20
$4.20
50-Day Range
$2.89
MA: $3.62
$4.20
52-Week Range
$1.56
Now: $4.20
$4.20
Volume1.29 million shs
Average Volume957,579 shs
Market Capitalization$2.97 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.5
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. Read More…

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:BIOS
CUSIP09069N10
Phone312-940-2443

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$708.90 million
Book Value($1.12) per share

Profitability

Net Income$-51,690,000.00

Miscellaneous

Employees2,043
Market Cap$2.97 billion
Next Earnings Date3/20/2020 (Estimated)
OptionableOptionable

Receive BIOS News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOS and its competitors with MarketBeat's FREE daily newsletter.


BioScrip (NASDAQ:BIOS) Frequently Asked Questions

What is BioScrip's stock symbol?

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

How were BioScrip's earnings last quarter?

BioScrip Inc (NASDAQ:BIOS) announced its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.01). The firm had revenue of $615.88 million for the quarter, compared to analyst estimates of $522.20 million. BioScrip had a negative net margin of 7.19% and a negative return on equity of 42.56%. View BioScrip's Earnings History.

When is BioScrip's next earnings date?

BioScrip is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for BioScrip.

What price target have analysts set for BIOS?

5 brokers have issued twelve-month price objectives for BioScrip's stock. Their forecasts range from $2.51 to $4.25. On average, they expect BioScrip's share price to reach $3.69 in the next year. This suggests that the stock has a possible downside of 12.1%. View Analyst Price Targets for BioScrip.

What is the consensus analysts' recommendation for BioScrip?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioScrip in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioScrip.

What are Wall Street analysts saying about BioScrip stock?

Here are some recent quotes from research analysts about BioScrip stock:
  • 1. According to Zacks Investment Research, "Option Care Health exited the third quarter with in-line loss but revenues ahead of the consensus mark. We are optimistic about the company’s huge integration-related synergy benefits. Management stated that it is expected to generate revenues exceeding $2.6 billion. The merger is expected to result in an optimized capital structure and enhance the financial strength and flexibility. The company’s consistent growth in the Infusion services business and the diverse measures adopted by management to drive growth bolsters our confidence in the stock. In the last six months, Option Care Health has consistently outperformed the industry it belongs to. On the flip side, regulatory restrictions, reimbursement cuts and a competitive landscape are a few of the factors affecting revenue growth of the legacy BioScrip over the recent past." (11/18/2019)
  • 2. Barrington Research analysts commented, "We think they should have held one given that management is currently engaged in selling BIOS investors on the benefits of the pending Option Care transaction." (5/3/2019)

Has BioScrip been receiving favorable news coverage?

Media coverage about BIOS stock has been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioScrip earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for BioScrip.

Are investors shorting BioScrip?

BioScrip saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 10,610,000 shares, an increase of 6.0% from the November 28th total of 10,010,000 shares. Based on an average daily trading volume, of 973,800 shares, the days-to-cover ratio is presently 10.9 days. Approximately 8.0% of the company's shares are short sold. View BioScrip's Current Options Chain.

Who are some of BioScrip's key competitors?

What other stocks do shareholders of BioScrip own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioScrip investors own include Abraxas Petroleum (AXAS), Northern Oil & Gas (NOG), Trevena (TRVN), Acasti Pharma (ACST), Advanced Micro Devices (AMD), Opko Health (OPK), General Electric (GE), Amarin (AMRN), AbbVie (ABBV) and Ford Motor (F).

Who are BioScrip's key executives?

BioScrip's management team includes the folowing people:
  • Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 54)
  • Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)
  • Ms. Harriet Booker, Sr. VP & COO (Age 52)
  • Mr. John McMahon, VP, Controller & Chief Accounting Officer (Age 54)
  • Mr. Vito Ponzio Jr., Chief Admin. Officer & Sr. VP (Age 64)

How do I buy shares of BioScrip?

Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioScrip's stock price today?

One share of BIOS stock can currently be purchased for approximately $4.20.

How big of a company is BioScrip?

BioScrip has a market capitalization of $2.97 billion and generates $708.90 million in revenue each year. The company earns $-51,690,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. BioScrip employs 2,043 workers across the globe.View Additional Information About BioScrip.

What is BioScrip's official website?

The official website for BioScrip is http://www.optioncarehealth.com/.

How can I contact BioScrip?

BioScrip's mailing address is 3000 Lakeside Dr. Suite 300N, Bannockburn IL, 60015. The company can be reached via phone at 312-940-2443 or via email at [email protected]


MarketBeat Community Rating for BioScrip (NASDAQ BIOS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  323 (Vote Outperform)
Underperform Votes:  294 (Vote Underperform)
Total Votes:  617
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel